Aim:
Aims: To evaluate useful variations in ABCG2 gene in relation to reaction of epileptic tablets in people with partial epilepsy. Additionally, explore opportunity of blended outcomes of variations in more than one transporter genes.

Material and methods:
Materials and methods: The study included sixty-five sufferers and forty healthful people; there were no top notch versions in phrases of age, gender, antiseizure medication therapy, or precise kinds of prescription drugs used. Polymorphism testing involved DNA extraction from the sample. Data pertaining to studies that examined correlation between ABCG2 polymorphisms were sought out. A total of 105 individuals, 65 of whom were patients and 40 of whom were healthy controls, were enrolled from October 2023 to April 2024 in this case-control research that took place in a hospital setting.

Results:
Results: Common age of sufferers turned into 22.51 ± 5.89 years, while manage organization had a median age of 19.24 ± 3.77 years. Distribution of sufferers and control individuals had a comparable frequency, with no brilliant disparities in terms of gender, antiseizure drug therapy, or antiseizure remedy kind. The heterozygous genotype CT became observed to be greater commonplace in patients compared to the manage group. The correlation among the ABCG2 C>T poly allele polymorphism and the risk of epilepsy was quite widespread.

Conclusions:
Conclusions: Overall, the study found that the ABCG2 C>T (rs2231137) polymorphism is associated with an increased risk of epilepsy. Specifically, the patient group was more likely to have the heterozygous genotype CT, with the allele C, compared to the control group.